U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07652983) titled 'TTE Study of QL1706 in Recurrent/Metastatic Cervical Cancer' on June 11.
Brief Summary: The goal of this observational study is to evaluate the effectiveness and safety of Iparomlimab and Tuvonralimab (QL1706)-based therapy in patients with recurrent or metastatic cervical cancer who have experienced disease progression after platinum-based treatment.
The main questions it aims to answer are:
* Does QL1706-based therapy improve clinical outcomes compared with investigator-selected chemotherapy in patients with recurrent or metastatic cervical cancer?
* Does the addition of bevacizumab further improve treatment effectiveness?
* W...